RxDoctor Payments DataLook up a doctor →

Amy Kemmerlin, NP

Women's Health · Charlotte, NCNPI 1891389656

Payments from drug & device makers

$8,202in general payments, 2019–2025

Across 319 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$756
  • Johnson & Johnson$489
  • Novartis$477
  • Astellas Pharma US Inc$458
  • Pfizer$362
  • Merck$309
  • plus $5K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)25$756
Johnson & Johnson(2 entities)17$489
Novartis20$477
Astellas Pharma US Inc12$458
Pfizer18$362
Merck14$309
Eisai Inc.12$268
Incyte Corporation9$261
Takeda Pharmaceuticals U.S.A., Inc.9$244
Stemline Therapeutics Inc.6$219
E.r. Squibb & Sons, L.L.C.9$213
AVEO Pharmaceuticals, Inc.6$200
Daiichi Sankyo Inc.4$192
AbbVie7$189
Amgen10$171
Bayer3$163
Novocure Inc.5$161
Sanofi6$156
Pharmacosmos Therapeutics Inc.5$132
Exelixis Inc.7$129
Genentech USA, Inc.5$121
Servier Pharmaceuticals LLC5$111
Puma Biotechnology, Inc.1$110
Jazz Pharmaceuticals Inc.5$109
Global Blood Therapeutics, Inc.1$108
Regeneron Healthcare Solutions, Inc.4$104
Karyopharm Therapeutics Inc.4$102
Boehringer Ingelheim4$98
Array Biopharma Inc5$97
Mirati Therapeutics, Inc.4$88
Sanofi-aventis U.S. LLC1$87
ADC Therapeutics America, Inc.5$85
Bristol Myers Squibb4$83
Beigene USA, Inc.4$81
GSK4$81
Taiho Oncology, Inc.4$79
Coherus Oncology, Inc.4$75
Pharmacyclics LLC, An Abbvie Company4$67
Accord Healthcare, Inc.3$64
Lilly USA, LLC3$61
Genmab U.S., Inc.2$54
Morphosys, US Inc.3$52
Deciphera Pharmaceuticals Inc.2$49
Amneal Pharmaceuticals LLC2$47
Seagen Inc.2$45
Acrotech Biopharma Inc.2$45
Beone Medicines USA, Inc.2$43
Adaptive Biotechnologies Corporation2$42
Alnylam Pharmaceuticals Inc.2$41
Tersera Therapeutics LLC2$39
Spectrum Pharmaceuticals Inc.2$39
Gilead2$36
Rigel Pharmaceuticals, Inc.2$31
Fresenius Kabi USA, LLC1$30
Recordati_rare_diseases_inc.1$28
Tempus AI, Inc1$25
Epizyme, Inc.1$22
Agios Pharmaceuticals, Inc.1$22
CTI Biopharma Corp.1$21
Phadia US Inc.1$19

How this compares

$8,202 in reported general payments places this provider in the 95th percentile of 158 women's health providers in North Carolina.

See all women's health providers in North Carolina →

Medicare billing

Part B allowed, 2024
$27,695
Medicare patients
17
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other women's health in Charlotte

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →